Not The Way You Want To Start Your Year: Inspire Cystic Fibrosis Drug Fails Late
This article was originally published in The Pink Sheet Daily
Executive Summary
Denufosol, a potentially disease-altering CF drug, was headed for an NDA filing later this year based on positive Phase III TIGER-1 data, but that was before the bad news from TIGER-2.
You may also be interested in...
Cystic Fibrosis Market Snapshot: Disease-Modifying Drugs Elusive 24 Years After Discovery Of Root Cause
The discovery in 1989 of the underlying genetics causing cystic fibrosis was expected to spur broad development of disease-modifying therapies. As of 2013, however, only one such drug is on the market, for a small subset of CF patients, and a few other candidates are in clinical development.
Merck's Latest Inspiration Is Bolt-On Acquisition of Inspire Pharma for $430M
The troubled specialty pharma offers Merck immediate revenues in ophthalmology, while the Big Pharma waits for approval of a new drug, Saflutan, for glaucoma and ocular hypertension.
Merck's Latest Inspiration Is Bolt-On Acquisition of Inspire Pharma for $430M
The troubled specialty pharma offers Merck immediate revenues in ophthalmology, while the Big Pharma waits for approval of a new drug, Saflutan, for glaucoma and ocular hypertension.